NEXT-LEVEL WOUND CONTROL WITH PURAPLY® AM
PuraPly AM is intended for the management of wounds and as an effective barrier to resist microbial colonization within the device and reduce microbes penetrating through the device.1
NEW STANDARD OF CARE
Take control before biofilm re-forms. Use PuraPly AM as early as day 1.* Bioburden management with PuraPly AM following sharp debridement helps you move wounds out of the inflammatory phase.
- Provides a proactive foundation of care for controlling bioburden and preventing biofilm re-formation†2-4
- Produces a sustained antimicrobial barrier effect between weekly debridements5,6
- Eliminates at-home primary dressing changes by the patient and/or caregiver1
See how PuraPly AM helps you take control of the healing environment in the mechanism of action video below.PRODUCT DETAILS
*Certain local coverage determinations may not allow skin substitute use until after conventional care at week 4
†Biofilm can re-form within 1-3 days7,8
THE POWER OF PLUS
Only PuraPly AM combines native, cross-linked ECM and broad-spectrum PHMB to provide a sustained antimicrobial barrier.
BRIDGE BETWEEN DEBRIDEMENTS
Only PuraPly AM combines native, cross-linked ECM + broad-spectrum PHMB
- Provides a sustained antimicrobial barrier effect5,6
- Helps prevent biofilm re-formation5
- Acts as a bridge between weekly debridements5
- Keeps you in control of the healing environment
Weekly PuraPly AM applications can help increase patient compliance as well as lead to office efficiencies, such as regularly scheduled patient visits.
THE POWER OF PLUS: INDEPENDENTLY UNIQUE, COLLECTIVELY IN CONTROL
NATIVE, CROSS-LINKED ECM
Quenches excess protease activity8,9
Unlike fragmented, reconstituted collagen:
- Native ECM inhibits a wider range of MMPs, helping to address the proinflammatory proteolytic environment that stalls wounds9
- The cross-linked, dual layers of PuraPly AM resist ECM degradation in the wound, supporting persistence between debridements3,8
- The native ECM fibers of PuraPly AM have been uniquely strengthened with EDC to increase the number of molecular bonds, which improves their resistance to protease degradation9-11
- The dual layers of PuraPly AM maximize surface area for PHMB saturation1,3,8
Proprietary purification process
- Preserves the natural matrix structure to ensure strength, function, and biocompatibility during wound healing
- Removes cells and non-collagen materials that could cause an inflammatory/immunologic response
- Inactivates viruses and bacteria
Proactively disrupts bioburden1,3,4
Unlike silver dressings, PHMB:
- Does not damage key cells (eg, fibroblasts) involved in wound healing5,12
- Features high tissue compatibility and low cytotoxicity2,4,5,13
- Has no known instances of bacteria acquiring resistance2-4,14
- Provides a persistent antimicrobial barrier effect in PuraPly AM1,5
PERSPECTIVE PAPER SERIES
Specialists, nurses, and researchers across the wound care space provide their perspectives on the impact of biofilm and the importance of biofilm management.
CONFIRMATION OF CONTROL
See more product details from PuraPly AM, including an application tutorial video, or contact an Organogenesis Tissue Regeneration Specialist to see how PuraPly AM can help your practice.
Please refer to the PuraPly AM Instructions for Use for complete prescribing information.
- PuraPly Antimicrobial [package insert]. Canton, MA: Organogenesis Inc; 2020.
- Hübner NO, et al. Skin Pharmacol Physiol. 2010;23(1 suppl):17-27.
- Brantley J, et al. Wounds Int. 2016;7(3):1-5.
- Gilbert P, et al. J Appl Microbiol. 2005;99(4):703-715.
- Davis SC, et al. Int Wound J. 2021. Epub ahead of print. doi:10.1111/iwj.13600
- Data on file. PDR-0001. Organogenesis Inc.
- Wolcott RD, et al. J Wound Care. 2010;19(8):320-328.
- Carpenter S, et al. Wounds. 2016;28(6 suppl):S1-S20.
- Negron I, et al. Int Wound J. 2014;11(4):392-397.
- Khor E. Biomaterials. 1997;18(2):95-105.
- Billiar K, et al. J Biomed Mater Res. 2001;56(1):101-108.
- Zou SB, et al. Int Wound J. 2013;10(3):306-312.
- Sood A, et al. Adv Wound Care. 2014;3(8):511-529.
- Sim W, et al. Antibiotics. 2018;7(4):93.